




FIG. 1




FIG. 2




FIG. 3




FIG. 4

Disease-Free Survival: HNSCC




FIG. 5

Overall Survival: HNSCC





FIG. 6


PFS and OS: SCLC Arms 1 & 2



Median PFS (95% CI): 9.3 months
(8.4, NC)
PFS12 (95% CI): 41.0% (19.8, 61.3)
PFS18 (95% CI): 34.2% (14.2, 55.5)
PFS24 (95% CI): 34.2% (14.2, 55.5)

FIG. 7

PFS and OS: SCLC Arms 1 & 2 by Treatment Arm




Arm 1		Arm 2	
Median PFS: 9.2 months (5.3, NC)		Median PFS: 16.6 months (8.4, NC)	
PFS12 (95% CI): 26.5% (4.4, 56.9)		PFS12 (95% CI): 53.0% (20.9, 77.3)	
PFS18 (95% CI): 26.5% (4.4, 56.9)		PFS18 (95% CI): 39.8% (11.0, 68.0)	
PFS24 (95% CI): 26.5% (4.4, 56.9)		PFS24 (95% CI): 39.8% (11.0, 68.0)	

FIG. 8

PFS and OS: SCLC Arms 3 & 4

WO 2024/052514


PCT/EP2023/074693



Median PFS (95% CI): NC
(6.3, NC)
PFS12 (95% CI): 77.8% (36.5, 93.9)
PFS18 (95% CI): 62.2% (21.3, 86.4)
PFS24 (95% CI): NC (NC, NC)

FIG. 9

PFS and OS: SCLC Arms 3 & 4 by Treatment Arm



Arm 3
Median PFS: NC (16.6, NC)
PFS12 (95% CI): 100.0% (100.0, 100.0)
PFS18 (95% CI): 75.0% (12.8, 96.1)
PFS24 (95% CI): NC (NC, NC)

FIG. 10

Arm 4
Median PFS: 9.3 months (6.3, NC)
PFS12 (95% CI): 33.3% (0.9, 77.4)
PFS18 (95% CI): 33.3% (0.9, 77.4)
PFS24 (95% CI): NC (NC, NC)